Results 101 to 110 of about 8,768 (188)

Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension.

, 2011
Background: Tadalafil 40 mg orally once daily, was shown to be well-tolerated and efficacious for pulmonary arterial hypertension in a 16-week, double-blind, placebo (PBO)-controlled trial.
Simonneau G, Oudiz RJ, Brundage BH, Response to Tadalafil Study Group, Beardsworth A, Ghofrani HA, Barst RJ, Sundin DP, Pulmonary Arterial Hypertension, GALIE', NAZZARENO   +9 more
core   +1 more source

ORAL ADMINISTRATION OF BOSENTAN ATTENUATES THE BLEOMYCIN INDUCED PULMONARY FIBROSIS IN MICE [PDF]

, 2014
Idiopathic Pulmonary Fibrosis (IPF) is characterized by alveolitis with epithelial, endothelial damage leading to fibrosis. As signaling of endothelin-1 was involved in IPF, the effect of bosentan a non-specific endothelin receptor antagonist was ...
Shanmuga Reddy Chilakapati, Damodar Reddy Chilakapati, Jagadeeswara Reddy Kanala, Pharm Res, Shanmuga Reddy Chilakapati Et Al, Pavan Kumar Manikonda, Mamatha Serasanambati   +6 more
core  

A randomised, controlled trial of bosentan in severe COPD

, 2008
Pulmonary hypertension during exercise is common in severe chronic obstructive pulmonary disease (COPD). It was hypothesised that the use of the endothelin-receptor antagonist bosentan can improve cardiopulmonary haemodynamics during exercise, thus ...
Tamm, M., Brutsche, M., Linka, A., Stolz, D., Di Valentino, M., Rasch, H., Meyer, A.   +6 more
core  

Liver injury due to endothelin receptor antagonists: a real-world study based on post-marketing drug monitoring data

Therapeutic Advances in Respiratory Disease
Background: Liver injury is the hallmark adverse reaction of endothelin receptor antagonist (ERA). Since the first drug, bosentan has been widely used in clinical practice, hepatotoxicity has been accompanied by the history of ERA.
Shichao Dong, Xiaofei Guo, Huayu Wang, Chuan Sun   +3 more
doaj   +1 more source

Successful Treatment with Bosentan for Pulmonary Hypertension and Reduced Peripheral Circulation in Juvenile Systemic Sclerosis

Pulmonary arterial hypertension (PAH) when associated with systemic sclerosis (SSc) (SSc-PAH) is one of the leading causes of mortality and is found in 10-15% of adult patients with SSc.
Shimizu, Masaki, Takehara, Kazuhiko, Ohta, Kunio, Hashida, Yoko, Yokoyama, Tadafumi, Saito, Takekatsu, Yachie, Akihiro, Nakayama, Yuko, Ueno, Kazuyuki   +8 more
core  

Bosentan

Drugs in R & D, 1999
openaire   +2 more sources

A new <i>in vitro</i> rat liver platform capturing biological diversity for drug-induced liver injury assessment and reduction of animal use in drug discovery and development. [PDF]

Front Toxicol
Wangikar P, Cherradi S, Choudhari P, Wangikar A, Madiwal V, Roux S, Banerjee N, Panzade P, Gangarde P, Kannan N, Duong HT.   +10 more
europepmc   +1 more source

Role for endothelin-1 in cardiometabolic dysfunction with intermittent hypoxia. [PDF]

Function (Oxf)
Gonsalves AM, Baker SE, Singh P, Limberg JK.   +3 more
europepmc   +1 more source

Multiple-dose pharmacokinetics, safety, and tolerability of bosentan, an endothelin receptor antagonist, in healthy male volunteers

, 1999
The multiple-dose pharmacokinetics, safety, and tolerability of oral bosentan, a selective endothelin receptor antagonist, were investigated in healthy male volunteers.
Viischer, H W., Hopfgartner, Gerard, Jonkman, J H., Schmitt, R., Meyer, Jean-Marc, Birnboeck, H., van Marle, S., Weber, Claude, Eggers, H.   +8 more
core  

Prophylactic Effects of Combined Bosentan and Nintedanib on Early Post-Traumatic Joint Contracture Formation in a Rat Model. [PDF]

J Clin Med
Wegner E, Warnke D, Buschmann V, Pirkl A, Betz M, Ritz U, Mühlschlegel TS, Dietz SO, Gercek E, Baranowski A.   +9 more
europepmc   +1 more source